Tissue plasminogen activator (tPA) in acute ischaemic stroke

Time for collegiate communication and consensus

Christopher R. Levi, David J. Blacker, Christopher F. Bladin, Peters M. Boers, Brian R. Chambers, Laurence L. Chu, Alastair J. Corbett, Denis S. Crimmins, Stephen M. Davis, Geoffrey A. Donnan, David W. Dunbabin, John N. Fink, Judith H. Frayne, Richard P. Gerraty, Graeme J. Hankey, Suzanne J. Hodgkinson, James T. Hughes, Tim J. Ingall, Peter B. Landau, Richard I. Lindley & 12 others Paul W. Long, Romesh Markus, Elizabeth M. Mullins, Mark W. Parsons, Michael R P Pollack, Stephen J. Read, David M. Rosen, David W. Schultz, David E. Serisier, John D G Watson, Catherine E. Storey, Alessandro A. Zagami

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

■ Systematic reviews of randomised trials of tPA in acute ischaemic stroke indicate a clear benefit of treating selected patients within 3 hours of stroke onset. Moreover, a net benefit remained after adjustment for chance baseline imbalances between subgroups in stroke severity within one of these trials (National Institute of Neurological Disorders and Stroke [NINDS]). ■ Rates of favourable outcomes and intracranial haemorrhage comparable with those in randomised trials can be achieved in routine clinical practice; however, translation of net benefit from tPA therapy requires organised and coordinated stroke management across the continuum of care. ■ Prerequisites for well organised and coordinated acute stroke care are: consensus among care providers on the use of tPA; stroke-care teams spanning the gaps between pre-hospital care, emergency departments and stroke units; and collegiate relations and effective communication networks between care providers.

Original languageEnglish (US)
Pages (from-to)634-636
Number of pages3
JournalMedical Journal of Australia
Volume180
Issue number12
StatePublished - Jun 21 2004

Fingerprint

Tissue Plasminogen Activator
Consensus
Stroke
Communication
National Institute of Neurological Disorders and Stroke
Continuity of Patient Care
Intracranial Hemorrhages
Hospital Emergency Service

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Levi, C. R., Blacker, D. J., Bladin, C. F., Boers, P. M., Chambers, B. R., Chu, L. L., ... Zagami, A. A. (2004). Tissue plasminogen activator (tPA) in acute ischaemic stroke: Time for collegiate communication and consensus. Medical Journal of Australia, 180(12), 634-636.

Tissue plasminogen activator (tPA) in acute ischaemic stroke : Time for collegiate communication and consensus. / Levi, Christopher R.; Blacker, David J.; Bladin, Christopher F.; Boers, Peters M.; Chambers, Brian R.; Chu, Laurence L.; Corbett, Alastair J.; Crimmins, Denis S.; Davis, Stephen M.; Donnan, Geoffrey A.; Dunbabin, David W.; Fink, John N.; Frayne, Judith H.; Gerraty, Richard P.; Hankey, Graeme J.; Hodgkinson, Suzanne J.; Hughes, James T.; Ingall, Tim J.; Landau, Peter B.; Lindley, Richard I.; Long, Paul W.; Markus, Romesh; Mullins, Elizabeth M.; Parsons, Mark W.; Pollack, Michael R P; Read, Stephen J.; Rosen, David M.; Schultz, David W.; Serisier, David E.; Watson, John D G; Storey, Catherine E.; Zagami, Alessandro A.

In: Medical Journal of Australia, Vol. 180, No. 12, 21.06.2004, p. 634-636.

Research output: Contribution to journalArticle

Levi, CR, Blacker, DJ, Bladin, CF, Boers, PM, Chambers, BR, Chu, LL, Corbett, AJ, Crimmins, DS, Davis, SM, Donnan, GA, Dunbabin, DW, Fink, JN, Frayne, JH, Gerraty, RP, Hankey, GJ, Hodgkinson, SJ, Hughes, JT, Ingall, TJ, Landau, PB, Lindley, RI, Long, PW, Markus, R, Mullins, EM, Parsons, MW, Pollack, MRP, Read, SJ, Rosen, DM, Schultz, DW, Serisier, DE, Watson, JDG, Storey, CE & Zagami, AA 2004, 'Tissue plasminogen activator (tPA) in acute ischaemic stroke: Time for collegiate communication and consensus', Medical Journal of Australia, vol. 180, no. 12, pp. 634-636.
Levi CR, Blacker DJ, Bladin CF, Boers PM, Chambers BR, Chu LL et al. Tissue plasminogen activator (tPA) in acute ischaemic stroke: Time for collegiate communication and consensus. Medical Journal of Australia. 2004 Jun 21;180(12):634-636.
Levi, Christopher R. ; Blacker, David J. ; Bladin, Christopher F. ; Boers, Peters M. ; Chambers, Brian R. ; Chu, Laurence L. ; Corbett, Alastair J. ; Crimmins, Denis S. ; Davis, Stephen M. ; Donnan, Geoffrey A. ; Dunbabin, David W. ; Fink, John N. ; Frayne, Judith H. ; Gerraty, Richard P. ; Hankey, Graeme J. ; Hodgkinson, Suzanne J. ; Hughes, James T. ; Ingall, Tim J. ; Landau, Peter B. ; Lindley, Richard I. ; Long, Paul W. ; Markus, Romesh ; Mullins, Elizabeth M. ; Parsons, Mark W. ; Pollack, Michael R P ; Read, Stephen J. ; Rosen, David M. ; Schultz, David W. ; Serisier, David E. ; Watson, John D G ; Storey, Catherine E. ; Zagami, Alessandro A. / Tissue plasminogen activator (tPA) in acute ischaemic stroke : Time for collegiate communication and consensus. In: Medical Journal of Australia. 2004 ; Vol. 180, No. 12. pp. 634-636.
@article{c95b5c4dcd764174812464b01d956ac6,
title = "Tissue plasminogen activator (tPA) in acute ischaemic stroke: Time for collegiate communication and consensus",
abstract = "■ Systematic reviews of randomised trials of tPA in acute ischaemic stroke indicate a clear benefit of treating selected patients within 3 hours of stroke onset. Moreover, a net benefit remained after adjustment for chance baseline imbalances between subgroups in stroke severity within one of these trials (National Institute of Neurological Disorders and Stroke [NINDS]). ■ Rates of favourable outcomes and intracranial haemorrhage comparable with those in randomised trials can be achieved in routine clinical practice; however, translation of net benefit from tPA therapy requires organised and coordinated stroke management across the continuum of care. ■ Prerequisites for well organised and coordinated acute stroke care are: consensus among care providers on the use of tPA; stroke-care teams spanning the gaps between pre-hospital care, emergency departments and stroke units; and collegiate relations and effective communication networks between care providers.",
author = "Levi, {Christopher R.} and Blacker, {David J.} and Bladin, {Christopher F.} and Boers, {Peters M.} and Chambers, {Brian R.} and Chu, {Laurence L.} and Corbett, {Alastair J.} and Crimmins, {Denis S.} and Davis, {Stephen M.} and Donnan, {Geoffrey A.} and Dunbabin, {David W.} and Fink, {John N.} and Frayne, {Judith H.} and Gerraty, {Richard P.} and Hankey, {Graeme J.} and Hodgkinson, {Suzanne J.} and Hughes, {James T.} and Ingall, {Tim J.} and Landau, {Peter B.} and Lindley, {Richard I.} and Long, {Paul W.} and Romesh Markus and Mullins, {Elizabeth M.} and Parsons, {Mark W.} and Pollack, {Michael R P} and Read, {Stephen J.} and Rosen, {David M.} and Schultz, {David W.} and Serisier, {David E.} and Watson, {John D G} and Storey, {Catherine E.} and Zagami, {Alessandro A.}",
year = "2004",
month = "6",
day = "21",
language = "English (US)",
volume = "180",
pages = "634--636",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "12",

}

TY - JOUR

T1 - Tissue plasminogen activator (tPA) in acute ischaemic stroke

T2 - Time for collegiate communication and consensus

AU - Levi, Christopher R.

AU - Blacker, David J.

AU - Bladin, Christopher F.

AU - Boers, Peters M.

AU - Chambers, Brian R.

AU - Chu, Laurence L.

AU - Corbett, Alastair J.

AU - Crimmins, Denis S.

AU - Davis, Stephen M.

AU - Donnan, Geoffrey A.

AU - Dunbabin, David W.

AU - Fink, John N.

AU - Frayne, Judith H.

AU - Gerraty, Richard P.

AU - Hankey, Graeme J.

AU - Hodgkinson, Suzanne J.

AU - Hughes, James T.

AU - Ingall, Tim J.

AU - Landau, Peter B.

AU - Lindley, Richard I.

AU - Long, Paul W.

AU - Markus, Romesh

AU - Mullins, Elizabeth M.

AU - Parsons, Mark W.

AU - Pollack, Michael R P

AU - Read, Stephen J.

AU - Rosen, David M.

AU - Schultz, David W.

AU - Serisier, David E.

AU - Watson, John D G

AU - Storey, Catherine E.

AU - Zagami, Alessandro A.

PY - 2004/6/21

Y1 - 2004/6/21

N2 - ■ Systematic reviews of randomised trials of tPA in acute ischaemic stroke indicate a clear benefit of treating selected patients within 3 hours of stroke onset. Moreover, a net benefit remained after adjustment for chance baseline imbalances between subgroups in stroke severity within one of these trials (National Institute of Neurological Disorders and Stroke [NINDS]). ■ Rates of favourable outcomes and intracranial haemorrhage comparable with those in randomised trials can be achieved in routine clinical practice; however, translation of net benefit from tPA therapy requires organised and coordinated stroke management across the continuum of care. ■ Prerequisites for well organised and coordinated acute stroke care are: consensus among care providers on the use of tPA; stroke-care teams spanning the gaps between pre-hospital care, emergency departments and stroke units; and collegiate relations and effective communication networks between care providers.

AB - ■ Systematic reviews of randomised trials of tPA in acute ischaemic stroke indicate a clear benefit of treating selected patients within 3 hours of stroke onset. Moreover, a net benefit remained after adjustment for chance baseline imbalances between subgroups in stroke severity within one of these trials (National Institute of Neurological Disorders and Stroke [NINDS]). ■ Rates of favourable outcomes and intracranial haemorrhage comparable with those in randomised trials can be achieved in routine clinical practice; however, translation of net benefit from tPA therapy requires organised and coordinated stroke management across the continuum of care. ■ Prerequisites for well organised and coordinated acute stroke care are: consensus among care providers on the use of tPA; stroke-care teams spanning the gaps between pre-hospital care, emergency departments and stroke units; and collegiate relations and effective communication networks between care providers.

UR - http://www.scopus.com/inward/record.url?scp=3042814549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042814549&partnerID=8YFLogxK

M3 - Article

VL - 180

SP - 634

EP - 636

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 12

ER -